Automatic wireless monitoring useful for heart failure patientsFierceHealthITAutomatic wireless monitoring has been proved beneficial for chronic heart failure patients, a new trial presented at the recent European Society of Cardiology meeting in Amst…
Amgen, Cytokinetics Report Mixed Results for Heart Failure DrugTheStreet.comBut heart failure patients treated with the highest dose of the drug, known as omecamtiv mecarbil, were able to breathe easier and showed sufficient, additional clinical improv…
UPDATED: PhII flop clouds future of Amgen, Cytokinetics heart failure drugFierceBiotechCytokinetics shares ($CYTK) took a dive in early trading today after its partner Amgen ($AMGN) reported that an IV formulation of their heart failure drug omecamtiv …
Novartis drug to treat heart failure effective across patient groupsJagran PostAmsterdam: An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, c…
Amgen, Cytokinetics heart failure drug misses goal in studyReuters IndiaAMSTERDAM (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its fut…
Cytokinetics, Amgen: Heart Failure Drug Misses Primary EndpointNASDAQCytokinetics Inc. ( CYTK ) and Amgen Inc. ( AMGN ) said results from a mid-stage trial for their experimental drug for acute heart failure failed to meet its primary endpoint. Shares …
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in studyReuters UKAMSTERDAM, Sept 3 (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, l…
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in studyReutersAMSTERDAM, Sept 3 (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leav…
|
Cardiac Resynchronization Therapy Fails for Certain Heart Failure Patients
HealthCanal.com COLUMBUS, Ohio – Researchers announced today that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and the international clinical trial ended early to prevent potential harm to patients. Cardiac Resynchronization Therapy offers no benefit beyond ICD therapy in …Medical Xpress ECHO-CRT: Resynchronization no help, may be harmful in narrow-QRS heart …TheHeart.Org Electromagnets guide heart device implantation, reduce radiation exposureWebWire (press release) MedPage Today –Forbes all 5 news articles » |
Amgen drug misses endpoint in acute heart failure trialPMLiVEA drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial. During the ATOMIC-AHF trial involving 613 patients with…